The Therapeutic Potential of 4-1BB (CD137) in Cancer

Title: The Therapeutic Potential of 4-1BB (CD137) in Cancer

Volume: 5 Issue: 5

Author(s): Kyung-Ok Nam, Woo J. Kang, Byoung S. Kwon, Sung J. Kim and Hyeon-Woo Lee

Affiliation:

Keywords: cd t cells, cancer, signaling pathways

Abstract: Techniques for modulating immune cells for cancer therapy have been widely studied. One key approach that is being clinically tested is developing tumor-destructive cell-mediated immune responses by regulating co-stimulatory molecules. 4-1BB (CD137), a member of the TNF receptor family, is expressed following activation of T and NK cells. Recently, it has been reported that DCs also express 4-1BB. Crosslinking of 4-1BB provides a potent co-stimulatory signal for lymphocytes via signal transduction pathways that modulate a number of cellular responses. One remarkable response is stimulation of anti-tumor activity in vivo and in vitro. We here review the potential role of 4-1BB in cancer immunotherapy focusing on the cellular and molecular mechanisms involved.

Cite this article as:

Nam Kyung-Ok, Kang J. Woo, Kwon S. Byoung, Kim J. Sung and Lee Hyeon-Woo, The Therapeutic Potential of 4-1BB (CD137) in Cancer, Current Cancer Drug Targets 2005; 5 (5) . https://dx.doi.org/10.2174/1568009054629681